Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 12, 2013, Pages 1466-1470

  Kaplan, Henry G ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DESMIN; GLUCOCORTICOID; PROTEIN S 100; SORAFENIB; VEMURAFENIB;

ABDOMEN; ABDOMINAL WALL; ADULT; ARTICLE; BONE METASTASIS; BRACHIAL PLEXUS; CANCER PATIENT; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG WITHDRAWAL; EPITHELIOID CELL; ERYTHEMA; FEMALE; FEVER; GENE MUTATION; HISTOCHEMISTRY; HUMAN; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MIDDLE AGED; RASH; SCAPULA; SHOULDER; SKIN DEFECT; SKIN INDURATION; SKIN TUMOR; SPINDLE CELL; SYSTEMIC THERAPY; THORAX WALL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; MUTATION; NERVE SHEATH NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84891950188     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0173     Document Type: Article

References (26)

1. Sun D, Tainsky MA, Haddad R. Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy. Transl Oncologenomics 2012;5:1-7.
2. Bottillo I, Ahlquist T, Brekke H, et al. Germline and somatic NF1 mutations in sporadic and NF-1 associated malignant nerve sheath tumors. J Pathol 2009;217:693-701.
3. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013;123:340-347.
4. Ambrosini G, Cheema HS, Seetman S, et al. Sorafenib inhibits growth and MAPK signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2012;7:890-896.
5. Whittaker S, Kirk R, Hayward R, et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2010;2:35ra41.
6. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-3140.
7. Tiacci E, Frifonov V, Schiavoni G, et al. BRAF mutations in hairy cell leukemia. N Engl J Med 2011;364:2305-2315.
8. Serrano C, Simonetti S, Hernandez-Losa J, et al. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumors. Histopathology 2013;62:499-504.
9. Serrano C, Simonetti S, Hernandez J, et al. BRAF V600E mutations in benign and malignant nerve sheath tumors [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 10043.
10. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF v600e mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma, and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405.
11. Kumar R, Angelini S, Snellman E, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342-348.
12. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract 3534.
13. Chapman PB, Hauschild HA, Haanen RC, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
14. Girotti M, Marais R. Déjà vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov 2013;3:487-590.
15. Koivunen JP, Mermel C, Zejnullah K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
16. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
17. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-1774.
18. Flaherty KT, Jeffrey R, Infante JR, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
19. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:101-104.
20. Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19:657-667.
21. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013;3:520-533.
22. DeClue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:1233-1241.
23. Zou CY, Smith KD, Zhu QS, et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 2009;8:1157-1168.
24. Margolin K. BRAF inhibition and beyond in advanced melanoma. Lancet 2012;380:320-322.
25. Poulikakos PI, Persaud Y, Janakiraman MJ, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480:387-390.
26. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80:561-567.